2
01, 2025
3
04, 2024
23
03, 2024
14
02, 2024
Lorenza Rimassa et al., Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
adlitterio663392024-04-10T14:35:43+02:00
16
05, 2023
10
02, 2023
21
11, 2022
1
09, 2022
25
04, 2022
9
10, 2021